HKU Scholars Hub: Browsing DSpace

Browsing by Author Cheng, AL

Jump to: 0-9 A B C D E F G H I J K L M N O P Q R S T U V W X Y Z 中

or enter first few letters:

Showing results 1 to 9 of 9

	Title	Author(s)	Issue Date	Views
	Adaptation Of International Guidelines For Metastatic Colorectal Cancer: An Asian Consensus Journal:Clinical Colorectal Cancer	Cheng, AL Li, J Vaid, AK Ma, B Teh, CS Ahn, JB Bello, M Charoentum, C Chen, LT de Lima Lopes Jr, G Ho, GF Kong, HL Lam, KO Liu, TS Park, YS Sriuranpong, V Sudoyo, AW Wang, JY Zhang, J Zhang, SZ Ciardiello, F Kohne, CH Shaw, M Kim, TW	2014	199
	Asian consensus workshop report: Expert consensus guideline for the management of intermediate and advanced hepatocellular carcinoma in Asia Proceeding/Conference:Oncology	Han, KH Kudo, M Ye, SL Choi, JY Poon, RTP Seong, J Park, JW Ichida, T Chung, JW Chow, P Cheng, AL	2011	92
	Asian pacific association for the study of the liver consensus recommendations on hepatocellular carcinoma Journal:Hepatology International	Omata, M Lesmana, LA Tateishi, R Chen, PJ Lin, SM Yoshida, H Kudo, M Lee, JM Choi, BI Poon, RTP Shiina, S Cheng, AL Jia, JD Obi, S Han, KH Jafri, W Chow, P Lim, SG Chawla, YK Budihusodo, U Gani, RA Lesmana, CR Putranto, TA Liaw, YF Sarin, SK	2010	122
	Efficacy and safety of every-2-weeks cetuximab combined with FOLFOX or FOLFIRI as first-line therapy in patients with KRAS wild-type metastatic colorectal cancer (mCRC): an Asia-Pacific nonrandomized phase II study (APEC) Proceeding/Conference:Journal of Clinical Oncology	Cheng, AL Cornelio, GH Shen, L Price, TJ Yang, TS Chung, IJ Dai, G Lin, JK Sharma, A Yeh, KH Ma, B Zaatar, A Guan, ZZ Masood, N Srimuninnimit, V Yau, TCC Sarholz, B Lim, RSC	2013	143
	Efficacy, Tolerability, and Biomarker Analyses of Once-Every-2-Weeks Cetuximab Plus First-Line FOLFOX or FOLFIRI in Patients With KRAS or All RAS Wild-Type Metastatic Colorectal Cancer: The Phase 2 APEC Study Journal:Clinical Colorectal Cancer	Cheng, AL Cornelio, G Shen, L Price, T Yang, TS Chung, IJ Dai, GH Lin, JK Sharma, A Yeh, KH Ma, B Zaatar, A Guan, Z Masood, N Srimuninnimit, V Yau, TCC Gibbs, P Wang, X Doval, DC Seung-Taek, O Shim, BY Gorospe, C Wang, HM Sirachainan, E Hill, A Suh, KW Beier, F Chatterjee, S Lim, R	2017	34
	Liver cancer working group report Journal:Japanese Journal of Clinical Oncology	Kudo, M Han, KH Kokudo, N Cheng, AL Choi, BI Furuse, J Izumi, N Park, JW Poon, RT Sakamoto, M	2010	65
	Management of colon cancer: resource-stratified guidelines from the Asian Oncology Summit 2012 Journal:Lancet Oncology	Ku, G Tan, IB Yau, TCC Boku, N Laohavinij, S Cheng, AL Kang, YK de Lima Lopes, G	2012	182
	Randomized, open-label phase 2 study comparing frontline dovitinib versus sorafenib in patients with advanced hepatocellular carcinoma Journal:Hepatology	Cheng, AL Thongprasert, S Lim, HY Sukeepaisarnjaroen, W Yang, TS Wu, CC Chao, Y Chan, SL Kudo, M Ikeda, M Kang, YK Pan, H Numata, K Han, G Balsara, B Zhang, Y Rodriguez, AM Zhang, Y Wang, Y Poon, RTP	2016	52
	Recent advances in the prevention of hepatocellular carcinoma recurrence Journal:Seminars in Liver Disease	Lu, LC Cheng, AL Poon, RTP	2014	169

Showing results 1 to 9 of 9